Importer of Controlled Substances Application: Fresenius Kabi USA, LLC, 54601-54602 [2016-19434]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 158 / Tuesday, August 16, 2016 / Notices
54601
SUPPLEMENTARY INFORMATION:
Oxford, MD 21654
DEPARTMENT OF JUSTICE
Authority: The authority for institution of
this investigation is contained in section 337
of the Tariff Act of 1930, as amended, and
in section 210.10 of the Commission’s Rules
of Practice and Procedure, 19 CFR 210.10
(2016).
Dorado Soapstone LLC
940 S. Jason St., Unit 9
Denver, CO 80223
Drug Enforcement Administration
Having
considered the complaint, the U.S.
International Trade Commission, on
August 10, 2016, Ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain quartz slabs and
portions thereof (II) by reason of
infringement of the claim of the ’666
patent; the claim of the ’670 patent; the
claim of the ’298 patent; the claim of the
’161 patent; and the claim of the ’058
patent, and whether an industry in the
United States exists as required by
subsection (a)(2) of section 337;
(2) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is:
Cambria Company LLC
805 Enterprise Drive East
Suite H
Belle Plaine, MN 56011
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Stylen Quaza LLC DBA Vicostone USA
11620 Goodnight Lane, Suite 100
Dallas, TX 75229
Vicostone Joint Stock Company
Hoalac Hi-tech Park
Thachthat, Hanoi
Vietnam
Building Plastics Inc.
3263 Sharpe Avenue
Memphis, TN 38111
Fasa Industrial Corporation, Ltd.
10th Floor, Building T6, Wisdom New
Town
No. 2 Jihua Road, Chancheng District,
Foshan, Guangdong Province 528000
China
Foshan FASA Building Material Co.,
Ltd.
10th Floor, Building T6, Wisdom New
Town
No. 2 Jihua Road, Chancheng District,
Foshan, Guangdong Province 528000
China
Solidtops LLC
27964 Oxford Road
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SCOPE OF INVESTIGATION:
VerDate Sep<11>2014
18:36 Aug 15, 2016
Jkt 238001
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
Pental Granite and Marble Inc.
713 South Fidalgo Street
Seattle, WA 98108
ACTION:
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW., Suite
401, Washington, DC 20436; and
(5) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Chief Administrative Law Judge
is authorized to consolidate Inv. No.
337–TA–996 and this investigation if he
deems it appropriate.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: August 11, 2016.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2016–19498 Filed 8–15–16; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Notice of application.
Registered bulk
manufacturers of the affected basic
class, and applicants therefor, may file
written comments on or objections to
the issuance of the proposed registration
in accordance with 21 CFR 1301.34(a)
on or before September 15, 2016. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
September 15, 2016.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
13, 2016, Fresenius Kabi USA, LLC,
3159 Staley Road, Grand Island, New
York 14072 applied to be registered as
an importer of remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans to import the
listed controlled substance for product
SUMMARY:
E:\FR\FM\16AUN1.SGM
16AUN1
54602
Federal Register / Vol. 81, No. 158 / Tuesday, August 16, 2016 / Notices
In accordance with 21 CFR
1301.34(a), this is notice that on June
29, 2016, ALMAC Clinical Services
Incorp (ACSI), 25 Fretz Road,
Souderton, Pennsylvania 18964 applied
to be registered as an importer of the
following basic classes of controlled
substances:
development and preparation of
stability batches.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–19434 Filed 8–15–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Controlled substance
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: ALMAC Clinical Services
Incorp (ACSI)
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before September 15, 2016. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
September 15, 2016.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
DATES:
VerDate Sep<11>2014
18:36 Aug 15, 2016
Jkt 238001
Schedule
Oxycodone (9143) ................
Hydromorphone (9150) ........
Morphine (9300) ...................
Tapentadol (9780) ................
Fentanyl (9801) ....................
II
II
II
II
II
The company plans to import the
listed controlled substances in dosage
form for clinical trial only. Approval of
permit applications will occur only
when the registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–19439 Filed 8–15–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Controlled substance
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cody Laboratories, Inc.
ACTION:
Notice of application.
Registered bulk
manufacturers of the affected basic
classes, and applicants therefore, may
file written comments on or objections
to the issuance of the proposed
registration in accordance with 21 CFR
1301.34(a) on or before September 15,
2016. Such persons may also file a
written request for a hearing on the
application pursuant to 21 CFR 1301.43
on or before September 15, 2016.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Attn: DEA Federal Register
Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on May 18,
2016, Cody Laboratories, Inc., 601
Yellowstone Avenue, Barry Baldwin,
Controlled Substances Manager, Cody,
Wyoming 82414–9321 applied to be
registered as an importer of the
following basic classes of controlled
substances:
Schedule
Phenylacetone (8501) ..........
Poppy Straw Concentrate
(9670) ................................
Tapentadol (9780) ................
II
II
II
The company plans to import narcotic
raw materials to manufacture bulk
controlled substances for distribution to
its customers. The company plans to
import an intermediate form of
tapentadol (9780), to bulk manufacture
tapentadol for distribution to its
customers.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–19435 Filed 8–15–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Actavis Laboratories FL.,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
DATES:
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 81, Number 158 (Tuesday, August 16, 2016)]
[Notices]
[Pages 54601-54602]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19434]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fresenius Kabi
USA, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Registered bulk manufacturers of the affected basic class, and
applicants therefor, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before September 15, 2016. Such persons may also file
a written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before September 15, 2016.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/ODW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated her
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
13, 2016, Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New
York 14072 applied to be registered as an importer of remifentanil
(9739), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
product
[[Page 54602]]
development and preparation of stability batches.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-19434 Filed 8-15-16; 8:45 am]
BILLING CODE 4410-09-P
